Inhibition of protein synthesis in intact HeLa cells.

Antimicrobial Agents and Chemotherapy
J S Tscherne, S Pestka

Abstract

Polysome analysis has proved to be a sensitive probe for the mode of action of inhibitors of protein synthesis in intact HeLa cells. To classify the active compounds as inhibitors of initiation, elongation, or termination, their effects on the cellular polyribosome pattern were compared under three conditions. These conditions tested (i) their direct effect on the polyribosome profile; (ii) their effect on ribosome run-off produced by hypertonicity; and (iii) their effects on recovery from hypertonicity. Using this technique, diacetoxyscirpenol, 2-(4-methyl-2,6-dinitroanilino)-N-methylpropionamide, and three alkaloids, harringtonine, isoharringtonine, and homoharringtonine, were found to be inhibitors of initiation. Polysome analysis indicated that in HeLa cells 7.8 x 10(-7) M pactamycin, which inhibited protein synthesis 94%, interfered with elongation as well as initiation under these conditions. Emetine, anisomycin, cycloheximide, and trichodermin each gave polysome patterns consistent with inhibition of elongation. Fusidic acid and aurintricarboxylic acid inhibited incorporation of [(14)C]leucine into intact HeLa cells, but polysome analysis did not localize any specific inhibitory effects to the initiation, elongation, or ...Continue Reading

References

Feb 15, 1968·Biochemical and Biophysical Research Communications·N TanakaH Masukawa
Aug 15, 1969·Biochemical and Biophysical Research Communications·W McKeehan, B Hardesty
Jan 1, 1969·Cold Spring Harbor Symposia on Quantitative Biology·D BaltimoreA S Huang
May 1, 1972·Journal of Virology·B E Butterworth, R R Rueckert
May 15, 1974·Journal of Molecular Biology·J L SaborioG Koch
Jan 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·E CundliffeJ Davies
Mar 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·C M WeiC S McLaughlin
Mar 1, 1972·Antimicrobial Agents and Chemotherapy·H L Ennis
Feb 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·T G Morrison, H F Lodish
Aug 1, 1973·Journal of Cellular Physiology·M E Stafford, C S McLaughlin
Nov 25, 1973·Journal of Molecular Biology·N S Petersen, C S McLaughlin
Jan 1, 1974·Methods in Enzymology·S Pestka
Apr 15, 1973·Journal of Molecular Biology·M H SchreierP F Spahr
Jan 1, 1971·Annual Review of Microbiology·S Pestka
Aug 1, 1972·Journal of Pharmaceutical Sciences·R G PowellC R Smith
Oct 9, 1970·Biochemical and Biophysical Research Communications·J S Macdonald, I H Goldberg

❮ Previous
Next ❯

Citations

Jan 1, 1987·Journal of Neuro-oncology·N SavarajT L Loo
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J L Ch'ngE W Holmes
Jan 1, 1977·European Journal of Biochemistry·M FresnoD Vázquez
Aug 24, 2011·The Journal of Cell Biology·Katharina RzeczkowskiMichael Kracht
Nov 26, 2015·Molecular Cell·Angelica FergusonScott C Blanchard
Oct 27, 2007·Cellular Microbiology·Michael H HühnMalin Flodström-Tullberg
Dec 29, 2004·Hematology·Chang Ying LuoYao Ping Wang
Mar 7, 2015·Nature Reviews. Drug Discovery·Mamatha BhatIvan Topisirovic
Jan 9, 2020·The Journal of Biological Chemistry·Mélissanne de WispelaerePriscilla L Yang
Nov 1, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jeff D ColbertKenneth L Rock
Dec 8, 2020·Biochemistry. Biokhimii︠a︡·S E DmitrievK A Lashkevich
Jan 25, 2021·The Journal of Biological Chemistry·Mélissanne de WispelaerePriscilla L Yang
Jun 1, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Luisa D Burgers, Robert Fürst
Oct 1, 1985·Experimental Cell Research·J Tannenbaum, J G Brett
Oct 18, 1996·The Journal of Organic Chemistry·Xiaodong LinPatrick S. Mariano

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.